On June 1, 2026, Jude Onyia, the Chief Scientific Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), executed a significant stock transaction, selling 11,000 shares for $1,762,710. The shares were sold at prices ranging from $160.00 to $160.66, just under the stock's 52-week high of $162.39. This sale was part of a Rule 10b5-1 trading plan established on February 25, 2026. Concurrently, Onyia exercised stock options to acquire the same number of shares at an exercise price of $84.74, totaling $932,140. Following these transactions, he holds 25,846 shares directly and 13,268 derivative shares. Neurocrine also reported strong financial results for the first quarter of 2026, with earnings per share of $1.94, significantly above expectations. The company’s revenue reached $811 million, exceeding forecasts. Additionally, Neurocrine completed a $2.9 billion acquisition of Soleno Therapeutics, which is expected to enhance revenue growth. Analysts have resumed coverage with positive ratings, noting the potential of Neurocrine’s key products.